Screener
Novavax NVAX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForCapitalImprovements.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Deferred revenue | (55,664) | (608,860) |
| Net cash used in operating activities | (105,230) | (312,964) |
| Investing Activities: | ||
| Capital expenditures, including internal-use software | (1,858) | (2,122) |
| Proceeds from assets held for sale | 39,750 | — |
| Purchases of marketable securities | (295,820) | (114,724) |
| Proceeds from maturities of marketable securities | 264,464 | 154,625 |
| Net cash provided by investing activities | 6,536 | 37,779 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's capex?
- Novavax (NVAX) reported capex of $588K in Q2 2026.
- How has Novavax's capex changed year-over-year?
- Novavax's capex increased by 11.6% year-over-year, from $527K to $588K.
- What is the long-term trend for Novavax's capex?
- Over 4 years (2021 to 2025), Novavax's capex has grown at a -43.5% compound annual growth rate (CAGR), from $54.5M to $5.56M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Novavax's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude